Examinando por Materia "Intususcepción"

Mostrando 1 - 2 de 2

Acceso abierto
Risk of intestinal invagination following the administration of the rotavirus vaccine in children under 2 years of age
(Universidad Privada Norbert Wiener, 2018-08-04) Caballero Maya, Ana Lucia; Jara Trujillo, Lourdes Aurora; Avila Vargas Machuca, Jeannette Giselle
Objective: To systematize the evidence on the risk of suffering from intestinal intussusception due to the application of rotavirus vaccine in infants under 2 years of age. Materials and Methods: Observational and retrospective systematic review, the search has been restricted to articles with full text, and the selected articles They were subjected to a critical reading, using the grade system to assign the strength of recommendation; where we find that 20% (02) correspond to India, China, Africa and 10% (01); Australia, Brazil, Mexico and Germany respectively Results: Of the total articles analyzed, 60% affirm that there is a risk of intestinal intussusception due to the application of the rotavirus vaccine in children under 2 years of age and 40% conclude that there is no risk of intussusception due to the administration of rotavirus vaccine. Conclusions: 6 of the reviewed articles show that there is a risk of intestinal intussusception due to the administration of the Rotavirus vaccine and 4 of the 10 reviewed articles show that there is a risk of intestinal intussusception due to the administration of the Rotavirus vaccine.
Acceso abierto
Risk of intussusception due to administration of the pentavalent RV5 vaccine versus the monovalent RV1 vaccine in children under 2 years old
(Universidad Privada Norbert Wiener, 2019-01-06) Gonzales Robles, Yeni Rosy; Pretell Aguilar, Rosa María
90% of studies conclude that there is a risk of intestinal intussusception due to administration of the RV1 and RV5 rotavirus vaccine; of which 50% show that there is a risk of intestinal intussusception for both types of biological RV5 and RV1; the same thing that happens within the first 7 days after application of the 1st dose of the vaccine. 20% of studies show that there is a greater risk of intussusception for the pentavalent vaccine Rotateq (RV5) in an interval of 1 to 7 days after applying the 1st dose and the remaining 20% of studies show that there is a risk of intussusception after application of the vaccine monovalent Rotarix (RV1) in a time interval of 1 week. 10% of studies conclude that current vaccines are effective and safe and pre-licensing studies with RV5 or RV1 did not show an increase in the frequency of intussusception and other serious adverse events; however, constant monitoring is recommended.